Tamoxifen or Cyproterone Acetate in Combination with Buserelin Are Ineffective in Patients with Pancreatic Adenocarcinoma

Clicks: 185
ID: 268240
1993
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Experimental evidence and preliminary clinical data suggest a responsiveness of pancreatic adenocarcinoma to sex hormones and LH-RH agonists. In this study, we investigated the effect of the antiestrogen tamoxifen and the anti-androgen cyproterone acetate in combination with the LH-RH agonist buserelin in 9 patients with unresectable pancreatic adenocarcinoma. In all patients the disease was progressive under this therapeutic regimen. In conclusion, complete androgen blockade and antiestrogens in combination with LH-RH agonist cannot be recommended in patients with widespread pancreatic adenocarcinoma.
Reference Key
arnold1993oncologytamoxifen Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors B. Swarovsky,M. Wolf,K. Havemann,R. Arnold;B. Swarovsky;M. Wolf;K. Havemann;R. Arnold;
Journal oncology
Year 1993
DOI 10.1159/000227184
URL
https://sciprofiles.com/publication/view/fc22be983f1e431b0fc84847cee981d9
Keywords
pancreatic carcinoma therapy antiandrogens antiestrogens lh-rh agonist

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.